Cytokine & Growth Factor Reviews
Volume 21, Issue 2 , Pages 99-102, April 2010

Virus therapy for bladder cancer

Billings Clinic, Department of Hematology and Oncology, United States

published online 12 April 2010.

Abstract 

Approximately 50,000 cases of superficial bladder cancer are diagnosed annually in the United States. Immunotherapy utilizing intravesical BCG is the most effective standard therapy for superficial transitional cell carcinoma of the bladder. Based on ease of administration, limited systemic dissemination, and the demonstrated activity of immunotherapy, superficial bladder cancer is an excellent target for virus based gene and immunotherapy. Thus far, clinical trials of virus therapy for bladder cancer have yielded mixed results. In this paper the results of several virus based clinical trials for bladder cancer are reviewed.

Keywords: Bladder cancer, Virus therapy, Immunotherapy, Adenovirus, GM-CSF, Gene therapy, CG0070, Vaccinia

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1359-6101(10)00014-6

doi:10.1016/j.cytogfr.2010.02.003

Cytokine & Growth Factor Reviews
Volume 21, Issue 2 , Pages 99-102, April 2010

Article Tools

* Image Usage & Resolution